SCHEMBL4086709

SCHEMBL4086709

CCOC(=O)c1c(I)c2sc(-c3ccc(C)s3)cc2n1Cc1cccc(Cl)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGES O14684 1/20 0.47
KMT2A Q03164 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
TP53 P04637 3/20 0.44
MEN1 O00255 1/20 0.43
LMNA P02545 1/20 0.43
HPGD P15428 1/20 0.43
KDR P35968 1/20 0.41
ALDH1A1 P00352 4/20 0.40
KDM4E B2RXH2 3/20 0.40
MAPT P10636 4/20 0.39
MAPK1 P28482 2/20 0.39
GRM5 P41594 1/20 0.38
ELANE P08246 1/20 0.38
TRPM8 Q7Z2W7 1/20 0.37
POLB P06746 1/20 0.37
TSHR P16473 1/20 0.37
ATM Q13315 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
PPARG P37231 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4096957 0.89 PTGES (0.52) PTGESTP53LMNAHPGDKDM4E
SCHEMBL4098784 0.85 TP53 (0.46) PTGESKMT2ASMN1; SMN2TP53MEN1
SCHEMBL4086539 0.76 PTGES (0.62) PTGESKMT2ASMN1; SMN2TP53MEN1
SCHEMBL4092264 0.74 PTGES (0.81) PTGESKMT2ASMN1; SMN2TP53MEN1
SCHEMBL4092463 0.72 CCR2 (0.55) PTGESTP53MAPT
SCHEMBL4086716 0.70 PTGES (0.50) PTGESKMT2AMEN1LMNAALDH1A1
SCHEMBL6092827 0.69 KMT2A (0.49) KMT2ASMN1; SMN2TP53MEN1LMNA
SCHEMBL4093394 0.68 CCR2 (0.55) LMNAHPGDKDM4EPTGDR2
SCHEMBL6090390 0.68 KMT2A (0.43) KMT2ASMN1; SMN2TP53MEN1LMNA
SCHEMBL19159661 0.68 TSHR (0.53) TP53LMNAALDH1A1KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090069384-A1 THIENOPYRROLES USEFUL IN THE TREATMENT OF INFLAMMATION BIOLIPOX AB (SE) 2009-03-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069384-A1 THIENOPYRROLES USEFUL IN THE TREATMENT OF INFLAMMATION NPY5R, TH, PTGES PTGES 3/4885KMT2A 4308/4885SMN1; SMN2 2913/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.